TSCAN THERAPEUTICS INC (TCRX) Forecast, Price Target & Analyst Ratings

NASDAQ:TCRX • US89854M1018

Current stock price

1.04 USD
0 (0%)
At close:
1.07 USD
+0.03 (+2.88%)
Pre-Market:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TSCAN THERAPEUTICS INC (TCRX).

Forecast Snapshot

Consensus Price Target

Price Target
$7.14
+ 586.54% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 4, 2026
Period
Q1 / 2026
EPS Estimate
-$0.21
Revenue Estimate
2.55M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
80.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$7.14
Upside
+ 586.54%
From current price of $1.04 to mean target of $7.14, Based on 13 analyst forecasts
Low
$4.04
Median
$6.12
High
$12.60

Price Target Revisions

1 Month
0.00%
3 Months
0.00%

Price Target Summary

13 Wall Street analysts provided a forecast for the next 12 months for TCRX. The average price target is 7.14 USD. This implies a price increase of 586.54% is expected in the next year compared to the current price of 1.04.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

TCRX Current Analyst RatingTCRX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6

Analyst Ratings History

TCRX Historical Analyst RatingsTCRX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
80.00%
TCRX was analyzed by 13 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about TCRX.
In the previous month the buy percentage consensus was at a similar level.
TCRX was analyzed by 13 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-05WedbushMaintains Outperform -> Outperform
2025-11-13HC Wainwright & Co.Maintains Buy -> Buy
2025-11-04BTIGDowngrade Buy -> Neutral
2025-11-04NeedhamMaintains Buy -> Buy
2025-05-07HC Wainwright & Co.Maintains Buy -> Buy
2025-04-08NeedhamReiterate Buy -> Buy
2025-03-07BarclaysMaintains Overweight -> Overweight
2025-03-06HC Wainwright & Co.Reiterate Buy -> Buy
2025-03-05NeedhamMaintains Buy -> Buy
2024-12-11NeedhamReiterate Buy -> Buy
2024-12-11HC Wainwright & Co.Reiterate Buy -> Buy
2024-11-15HC Wainwright & Co.Reiterate Buy -> Buy
2024-11-12NeedhamReiterate Buy -> Buy
2024-11-06NeedhamReiterate Buy -> Buy
2024-08-13WedbushReiterate Outperform -> Outperform
2024-08-13HC Wainwright & Co.Reiterate Buy -> Buy
2024-08-12NeedhamReiterate Buy -> Buy
2024-06-04HC Wainwright & Co.Reiterate Buy -> Buy
2024-05-16BTIGInitiate Buy
2024-05-14HC Wainwright & Co.Reiterate Buy -> Buy
2024-05-13NeedhamReiterate Buy -> Buy
2024-04-23WedbushReiterate Outperform -> Outperform
2024-03-07BarclaysMaintains Overweight -> Overweight
2024-03-07HC Wainwright & Co.Reiterate Buy -> Buy
2024-02-01WedbushReiterate Outperform -> Outperform

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 4, 2026
Period
Q1 / 2026
EPS Estimate
-$0.21
Revenue Estimate
2.55M
Revenue Q2Q
17.46%
EPS Q2Q
20.91%
Number of Analysts
7

Next Earnings Revisions

Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
-4.46%
EPS (3 Months)
-5.73%

Next Earnings Summary

TCRX is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is -0.21 USD and the consensus revenue estimate is 2.55M USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
TCRX revenue by date.TCRX revenue by date.
21.049M
55.46%		2.816M
-86.62%		10.325M
266.65%		8.638M
-16.34%		10.349M
19.81%		27.088M
161.75%		53.004M
95.67%		93.712M
76.80%		226.39M
141.58%		336.86M
48.80%		437.62M
29.91%
EBITDA
YoY % growth
TCRX ebitda by date.TCRX ebitda by date.
-88.097M
-43.25%		-130.713M
-48.37%		-130.947M
-0.18%		-140.998M
-7.68%		-151.247M
-7.27%		N/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
TCRX ebit by date.TCRX ebit by date.
-93.458M
-40.24%		-134.821M
-44.26%		-133.813M
0.75%		-113.975M
14.83%		-120.734M
-5.93%		-123.823M
-2.56%		-88.491M
28.53%		-29.858M
66.26%		50.141M
267.93%		134.93M
169.10%		184.76M
36.93%
Operating Margin
TCRX operating margin by date.TCRX operating margin by date.
-444.00%-4,787.68%-1,296.01%-1,319.46%-1,166.62%-457.11%-166.95%-31.86%22.15%40.06%42.22%
EPS
YoY % growth
TCRX eps by date.TCRX eps by date.
-1.89
31.27%		-1.15
39.15%		-1.00
13.04%		-0.91
8.69%		-0.87
4.60%		-0.93
-7.14%		-0.61
34.97%		-0.19
68.07%		0.31
257.89%		0.78
153.33%		1.03
32.24%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth		-0.21
20.91%		-0.20
26.96%		-0.21
24.50%		-0.20
-13.15%
Revenue
Q2Q % growth		2.55M
17.46%		1.913M
-37.81%		1.785M
-28.91%		1.53M
-40.40%
EBITDA
Q2Q % growth		N/AN/AN/AN/A
EBIT
Q2Q % growth		-24.631M
32.05%		-29.361M
24.04%		-30.532M
17.60%		-29.886M
-36.73%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

TCRX Yearly Revenue VS EstimatesTCRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
TCRX Yearly EPS VS EstimatesTCRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -2 -4 -6

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
2.18%
EPS Next 5 Year
12.55%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
35.48%
Revenue Next 5 Year
53.79%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

TSCAN THERAPEUTICS INC / TCRX Forecast FAQ

What is the average price target for TSCAN THERAPEUTICS INC (TCRX) stock?

13 analysts have analysed TCRX and the average price target is 7.14 USD. This implies a price increase of 586.54% is expected in the next year compared to the current price of 1.04.

When does TSCAN THERAPEUTICS INC (TCRX) report earnings?

TSCAN THERAPEUTICS INC (TCRX) will report earnings on 2026-05-04.

What are the consensus estimates for TSCAN THERAPEUTICS INC (TCRX) next earnings?

The consensus EPS estimate for the next earnings of TSCAN THERAPEUTICS INC (TCRX) is -0.21 USD and the consensus revenue estimate is 2.55M USD.

Can you provide the expected long term growth rate for TSCAN THERAPEUTICS INC stock?

The expected long term growth rate for TSCAN THERAPEUTICS INC (TCRX) is 35.48%.